Intellia End Period Cash Flow from 2010 to 2024
| NTLA Stock | USD 12.10 0.08 0.66% |
End Period Cash Flow | First Reported 2014-06-30 | Previous Quarter 130.8 M | Current Value 134.1 M | Quarterly Volatility 120.8 M |
Check Intellia Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intellia Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.9 M, Interest Expense of 10.3 M or Selling General Administrative of 122.3 M, as well as many indicators such as Price To Sales Ratio of 51.24, Dividend Yield of 0.0 or PTB Ratio of 2.74. Intellia financial statements analysis is a perfect complement when working with Intellia Therapeutics Valuation or Volatility modules.
Intellia | End Period Cash Flow |
Latest Intellia Therapeutics' End Period Cash Flow Growth Pattern
Below is the plot of the End Period Cash Flow of Intellia Therapeutics over the last few years. It is Intellia Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Intellia Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| End Period Cash Flow | 10 Years Trend |
|
End Period Cash Flow |
| Timeline |
Intellia End Period Cash Flow Regression Statistics
| Arithmetic Mean | 143,525,347 | |
| Geometric Mean | 73,157,866 | |
| Coefficient Of Variation | 106.25 | |
| Mean Deviation | 120,067,550 | |
| Median | 75,816,000 | |
| Standard Deviation | 152,501,988 | |
| Sample Variance | 23256.9T | |
| Range | 520.7M | |
| R-Value | 0.62 | |
| Mean Square Error | 15329.4T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | 21,239,580 | |
| Total Sum of Squares | 325596T |
Intellia End Period Cash Flow History
About Intellia Therapeutics Financial Statements
Intellia Therapeutics stakeholders use historical fundamental indicators, such as Intellia Therapeutics' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Intellia Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Intellia Therapeutics' assets and liabilities are reflected in the revenues and expenses on Intellia Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Intellia Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| End Period Cash Flow | 240.4 M | 207.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Intellia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intellia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intellia Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intellia Therapeutics Stock:Check out the analysis of Intellia Therapeutics Correlation against competitors. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.45) | Revenue Per Share 0.449 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.